Evidence Table D3: DISCRETE outcomes for class ANTI-BACTERIAL (TOPICAL)/KERATOLYTIC (TOPICAL).

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
	D.01.01			**Benzoyl peroxide**	**Vehicle**	
173 ↑ Parallel Mild/mod N=77		**Local reactions I**	Mid (12)	Scaling 7 Stinging 1 Itching 3 Peeling 2	Scaling 3 Stinging 2 Itching 0 Peeling 3	
		Local reactions II	Mid (12)	Erythema 10 Burning 3 soreness 3 Dryness 5 Roughness 1	Erythema 1 Burning 0 Soreness 0 Dryness 0 Roughness 1	
176 ↓ Parallel Mod/sev N=150		**Local effects**		Dryness, scaling, burning, stinging, redness 22 None 22	Dryness, scaling, burning, stinging, redness 5 None 41	**0.05**
	D.01.03			**Benzoyl peroxide**	**Gluconolactone**	
176 ↓ Parallel Mod/sev N=150		**Local effects**		Dryness, scaling, burning, stinging, redness 22 None 22	Dryness, scaling, burning, stinging, redness 11 None 34	**0.05**
	D.01.09			**Benzoyl peroxide (acetone)**	**Benzoyl peroxide (alcohol)**	
221 ↓ Parallel Mod N=147		**Severity change**	Mid (8)	Excellent 20 Good 15 Fair 11 Poor 8	Excellent 11 Good 8 Fair 11 Poor 8	**NS**
	D.05.01			**Benzoyl peroxide + erythromycin**	**Placebo**	
310 ↑ Parallel Mild/mod N=92		**Side effects**	Short (4)	Scaling or tightness 14	Scaling or tightness 3	**NS**
		Side effects Between P-value: For scaling and burning	Mid (12)	Scaling or tightness 13	Scaling or tightness 1	**0.05**
	D.05.02			**Erythromycin + benzoyl peroxide**	**Clindamycin phosphate**	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
260 ↑ Parallel Mild/mod N=205		**Side effects**	Mid (10)	Mild - moderate 3 Withdraw 3	Mild - moderate 1 Withdraw 0	
	D.05.04			**Benzoyl peroxide + erythromycin**	**Zinc + erythromycin**	
62 ↓ Parallel Mod N=72		**Improved by 50% or more**	Short (6)	Improved by 50% or more 22	Improved by 50% or more 8	
		Adverse effects	Mid (10)	Dryness/ irritation 1	Dryness/ irritation 4	
		Improved by 50% or more	Mid (10)	Improved by 50% or more 30	Improved by 50% or more 15	
	D.06.01			**Meclocycline + benzoyl peroxide**	**Benzoyl peroxide**	
30 ↑ Parallel Mod N=102		**Skin discoloration**	Mid (10)	Present 1 Absent 32	Present 1 Absent 35	
	D.07.01			**Benzoyl peroxide + metronidazole**	**Vehicle**	
121 ↑ Parallel Mod/sev N=43		**Overall change/patient**	Short (6)	Much worse 0 Worse 0 Unchanged 1 Somewhat improved 3	Much worse 0 Worse 0 Unchanged 11 Somewhat improved 1	**0.05**
		Overall change/patient	Short (6)	Improved 4 Much improved 15 0-25% 3 26-50% 2 51-75% 6 76-100% 12	Improved 6 Much improved 2 0-25% 9 26-50% 3 51-75% 8 76-100% 0	**0.05**
		Severity change/photo	Short (6)	0-25% 2 26-50% 5 51-75% 5 76-100% 11	0-25% 10 26-50% 4 51-75% 6 76-100% 0	**0.05**
	D.07.02			**Benzoyl peroxide + metronidazole**	**Benzoyl peroxide**	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
122 ↑ Parallel Mod/sev N=60		**Overall change/patient**	Short (6)	Much worse 0 Worse 0 Unchanged 4 Somewhat improved 1	Much worse 0 Worse 0 Unchanged 8 Somewhat improved 4	**0.05**
				Improved 7 Much improved 18	Improved 4 Much improved 13	
		Overall change/physician	Short (6)	0-25% 2 26-50% 2 51-75% 8 76-100% 18	0-25% 9 26-50% 3 51-75% 3 76-100% 14	**0.05**
		Severity change/photo	Short (6)	0-25% 3 26-50% 4 51-75% 4 76-100% 19	0-25% 8 26-50% 2 51-75% 3 76-100% 16	**0.05**
	D.08.01			**Benzoyl peroxide + miconazole**	**Benzoyl peroxide**	
231 ↑ Parallel Mild/mod/sev N=20		**Overall assessment/patient**	Mid (8)	Excellent 7 Good 5 Moderate 1 None 1	Excellent 5 Good 6 Moderate 2 None 3	
		Overall assessment/physician	Mid (8)	Excellent 7 Good 4 Moderate 2 None 1	Excellent 7 Good 4 Moderate 2 None 3	
		Side effects	Mid (8)	Present 3 Absent 11	Present 2 Absent 14	**NS**
	D.08.01			**Miconazole + benzoyl peroxide**	**Benzoyl peroxide**	
85 ↑ Parallel Mod N=105		**Severity change (score shift)**	Mid (8)	-3 0 -2 0 -1 0 0 3	-3 0 -2 0 -1 1 0 12	**0.001**
				+1 26 +2 19 +3 1	+1 28 +2 9 +3 0	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
85 ↑ Parallel Mod N=105		**Overall change/patient**	Mid (12)	Excellent 28 Good 17 Moderate 5 Bad 1	Excellent 10 Good 17 Moderate 21 Bad 3	**0.001**
		Overall change/physician	Mid (12)	Excellent 22 Good 21 Moderate 7 Bad 1	Excellent 8 Good 13 Moderate 23 Bad 7	**0.001**
		Severity change (score shift)	Mid (12)	-3 0 -2 0 -1 0 0 2	-3 0 -2 0 -1 2 0 8	**0.001**
				+1 15 +2 26 +3 4	+1 22 +2 16 +3 1	
		Side effects	Mid (12)	Irritation/dryness 1 Allergic reaction 0 None 50	Irritation/dryness 10 Allergic reaction 1 None 40	**0.005**

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.